Company Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 01:29:50 16/05/2024 am IST			5-day change	1st Jan Change
4 ^CAD	-0.25%		+1.01%	-25.51%

14/05	Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	MT
08/05	Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Companyâs principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.

Number of employees: 29

Managers	Title	Age	Since
James A. Helliwell FOU	Founder	-	23/12/23
Bruce G. Cousins DFI	Director of Finance/CFO	63	03/21/03
Amanda Malone COO	Chief Operating Officer	-	01/12/01
Mark M. Kowalski CTO	Chief Tech/Sci/R&D Officer	69	18/23/18
Vik Peck IRO	Public Communications Contact	-	-
Adam Peeler IRC	Investor Relations Contact	-	-
Murray Webb PRN	Corporate Officer/Principal	-	01/17/01
Ash Bassett PRN	Corporate Officer/Principal	-	-
Paul A. Brennan PRN	Corporate Officer/Principal	-	01/19/01

Members of the board	Title	Age	Since
Paul Geyer BRD	Director/Board Member	61	14/13/14
John Montalbano FOU	Founder	59	14/13/14
Richard Glickman BRD	Director/Board Member	65	09/21/09
Simon Pimstone CHM	Chairman	56	14/13/14
James A. Helliwell FOU	Founder	-	23/12/23
Michael Wilmink BRD	Director/Board Member	-	14/13/14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	35,622,553	33,235,348 ( 93.30 %)	0	93.30 %

Name	Equities	%	Valuation
Manchester Management Co. LLC 7.815 %	2,784,049	7.815 %	8 M $
Pathfinder Asset Management Ltd. (Canada) 3.885 %	1,384,000	3.885 %	4 M $
John Montalbano 3.362 %	1,197,666	3.362 %	3 M $
James A. Helliwell 1.892 %	674,012	1.892 %	2 M $
Paul Geyer 0.9554 %	340,346	0.9554 %	969 986 $
Michael Wilmink 0.6160 %	219,425	0.6160 %	625 361 $
Bruce G. Cousins 0.3208 %	114,286	0.3208 %	325 715 $
Faircourt Asset Management, Inc. 0.1755 %	62,500	0.1755 %	178 125 $
Amanda Malone 0.1301 %	46,343	0.1301 %	132 078 $
Paul A. Brennan 0.0764 %	27,200	0.0764 %	77 520 $

Eupraxia Pharmaceuticals, Inc.

2067 Cadboro Bay Road Suite 201

V8R 5G4, Victoria

http://www.eupraxiapharmaceuticals.com

address Eupraxia Pharmaceuticals Inc.(EPRX)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4 CAD

Average target price

14.45 CAD

Spread / Average Target

+261.25%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
EUPRAXIA PHARMACEUTICALS INC.	-25.51%	10Cr
MODERNA, INC.	+29.77%	4.95TCr
IQVIA HOLDINGS INC.	+1.00%	4.26TCr
LONZA GROUP AG	+50.30%	4.25TCr
CELLTRION, INC.	-5.26%	2.91TCr
ICON PUBLIC LIMITED COMPANY	+13.68%	2.66TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	1.86TCr
BIO-TECHNE CORPORATION	+8.22%	1.32TCr
MEDPACE HOLDINGS, INC.	+32.41%	1.25TCr
UNITED THERAPEUTICS CORPORATION	+24.01%	1.21TCr

Other Biotechnology & Medical Research